Texas Bank & Trust Co Purchases Shares of 13,215 Bristol-Myers Squibb (NYSE:BMY)

Texas Bank & Trust Co purchased a new position in Bristol-Myers Squibb (NYSE:BMY - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 13,215 shares of the biopharmaceutical company's stock, valued at approximately $747,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Truist Financial Corp grew its stake in Bristol-Myers Squibb by 3.9% in the fourth quarter. Truist Financial Corp now owns 1,597,150 shares of the biopharmaceutical company's stock worth $90,335,000 after purchasing an additional 60,365 shares during the period. Corundum Group Inc. grew its stake in shares of Bristol-Myers Squibb by 67.8% in the fourth quarter. Corundum Group Inc. now owns 43,534 shares of the biopharmaceutical company's stock worth $2,462,000 after acquiring an additional 17,596 shares during the last quarter. High Net Worth Advisory Group LLC grew its stake in shares of Bristol-Myers Squibb by 42.2% in the fourth quarter. High Net Worth Advisory Group LLC now owns 16,974 shares of the biopharmaceutical company's stock worth $960,000 after acquiring an additional 5,040 shares during the last quarter. KBC Group NV grew its stake in shares of Bristol-Myers Squibb by 18.4% in the fourth quarter. KBC Group NV now owns 4,054,868 shares of the biopharmaceutical company's stock worth $229,343,000 after acquiring an additional 628,908 shares during the last quarter. Finally, Quilter Plc grew its stake in shares of Bristol-Myers Squibb by 56.6% in the fourth quarter. Quilter Plc now owns 107,818 shares of the biopharmaceutical company's stock worth $6,098,000 after acquiring an additional 38,977 shares during the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

BMY has been the topic of a number of recent research reports. The Goldman Sachs Group reissued a "neutral" rating and issued a $55.00 target price (down from $67.00) on shares of Bristol-Myers Squibb in a research note on Tuesday, April 8th. William Blair reissued a "market perform" rating on shares of Bristol-Myers Squibb in a research note on Friday, April 25th. Argus raised Bristol-Myers Squibb to a "hold" rating in a research note on Friday, April 25th. Cantor Fitzgerald reissued a "neutral" rating and issued a $55.00 target price on shares of Bristol-Myers Squibb in a research note on Tuesday, April 22nd. Finally, Piper Sandler assumed coverage on Bristol-Myers Squibb in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 price objective on the stock. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have issued a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $58.00.

Bristol-Myers Squibb Stock Performance

Shares of NYSE BMY traded down $0.90 during trading on Wednesday, hitting $46.97. The company had a trading volume of 11,958,938 shares, compared to its average volume of 13,206,404. The stock has a 50 day simple moving average of $52.55 and a 200 day simple moving average of $55.89. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $63.33. The firm has a market capitalization of $95.58 billion, a P/E ratio of -10.63, a price-to-earnings-growth ratio of 2.07 and a beta of 0.39.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last issued its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.50 by $0.30. The company had revenue of $11.20 billion for the quarter, compared to the consensus estimate of $10.77 billion. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The firm's quarterly revenue was down 5.6% on a year-over-year basis. During the same quarter last year, the company earned ($4.40) EPS. As a group, analysts anticipate that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, May 1st. Investors of record on Friday, April 4th were paid a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a yield of 5.28%. The ex-dividend date was Friday, April 4th. Bristol-Myers Squibb's dividend payout ratio (DPR) is presently 92.88%.

Insider Activity at Bristol-Myers Squibb

In other news, EVP Samit Hirawat purchased 4,250 shares of the business's stock in a transaction on Friday, April 25th. The stock was acquired at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the acquisition, the executive vice president now directly owns 83,513 shares of the company's stock, valued at $3,973,548.54. This represents a 5.36% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.07% of the stock is owned by corporate insiders.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.